# SIMULTANEOUS SPECTROPHOTOMETRIC ESTIMATION OF ABACAVIR SULFATE AND LAMIVUDINE IN TABLET DOSAGE FORM BY Q-ANALYSIS METHOD 

## P. V. Duse*

## S. N. Mokale

T. D. Pingale


#### Abstract

Simultaneous Spectrophotometric Estimation of Abacavir sulfate and Lamivudine in Tablet Dosage Form by Q-Analysis method or Absorbance ratio method Simple, accurate and economic method Q-Analysis has been described for the simultaneous estimation of Abacavir and Lamivudine in tablet dosage form. Abacavir shows absorption maximum at 284.0 nm and Lamivudine shows absorption maximum at 270.0 nm in distilled water. Beers law was obeyed in the concentration range of $5-30 \mu \mathrm{~g} / \mathrm{ml}$ for Both Abacavir and Lamivudine. The coefficient correlations were found to be 0.9995 for LAM and 0.9992 for ABAC respectively.The method allows rapid analysis of binary pharmaceutical formulation with accuracy. Results of Tablet analysis by Q-Analysis or Absorbance ratio method was found to be $99.97 \%$ for ABAC and $99.99 \%$ for LAM respectively. Results of analysis of this method was validated statistically and by recovery studies and was found satisfactory.


Abacavir sulfate is \{(1S, 4R)-4-[2-Amino-6-cyclopropyl amino) 9H-Purin-9yl) cyclopent-2-enyl) methanol sulfate. it works by preventing HIV from infecting new cells and taking them over. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by its incorporation into viral DNA.

Lamivudine Chemically it is (2R,5S)-4-Amino1 [2-(Hydroxy methyl)1, 3-oxathiolan-5yl]-2(1H)-Pyrimidinedione. It is used in HIV infection. Lamivudine is phosphorylated to its active 5'triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. Both Abacavir sulfate (ABAC) and Lamivudine (LAM) are official in IP [1]. Both the Drugs are marketed as combined dose tablet formulation and the Ratio is $300: 600 \mathrm{mg}$ LAM: ABAC. Literature survey revealed that a number of methods have been reported for estimation of Abacavir sulfate individually or in combination with other drugs and Lamivudine or in combination with other drugs[2-13]. Present work describes two simple, accurate, reproducible, rapid and economical methods for simultaneous estimation of ABAC and LAM in tablet formulation.

A Jasco UV-VIS spectrophotometer model UVV-630 spectrophotometer was employed (spectral bandwidth 2 nm ) with a pair of 1 m quartz cell for the method of AUC and UV 1800 shimadzu (UV /Vis spectrophotometer) spectral bandwidth 2 nm with a pair of 1 m quartz cell employed for the method of Multicomponent mode. Standard gift sample of Abacavir sulfate and Lamivudine were provided by Aurobindo Ltd., Hyderabad. Distilled water used as a solvent. Stock solution $(100 \mu \mathrm{~g} / \mathrm{ml})$ of ABAC and LAM prepared by dissolving 10 mg of drug in 100 ml double distilled water. The maximum absorbance of ABAC and LAM obtained at 284.0 nm and 270.0 nm respectively. $A B A C$ and $L A M$ shows their respective linearity in the concentration range of $5-30 \mu \mathrm{~g} / \mathrm{ml}$ at their respective wavelength maxima.

For this method, same mixed standard in the linearity range for each drug from $5-30 \mu \mathrm{~g} / \mathrm{ml}$ of ABAC and LAM were prepared by diluting appropriate volumes of standard stock solutions. The scanning of
solution of ABAC and LAM was carried out in the range of $400 \mathrm{~nm}-$ 200nm.

In the simultaneous equation using Q-Analysis or Absorbance ratio method, However the Isobastic point was found to be at 265 nm . Thus the wavelength 284.0 nm with reference to 265.0 nm (Isobastic point) was feed to the instrument for analysis as sampling points.

Selection of standard to be used: after optimization the concentration of $15 \mathrm{mcg} / \mathrm{ml}$ of LAM and $30 \mathrm{mcg} / \mathrm{ml}$ of ABAC were found to give best results. The Q values and Molar Absorptivities for both drugs were calculated as follows:

| $\mathrm{Q}_{\text {LAM }}=$ | Absorbance of Std. 1 at 284nm |
| :---: | :---: |
|  | Absorbance of Std. 1 at 265nm |
| $\mathrm{Q}_{\text {ABAC }}=$ | Absorbance of Std. 2 at 284 nm |
|  | Absorbance of Std. 2 at 265nm |
| $\mathrm{A}_{\text {LAM }}=$ | Absorbance of Std. 1 at 265nm |
|  | Concentration of Std. 1 in gms/lit |
| $\mathrm{A}_{\text {ABAC }}=$ | Absorbance of Std. 2 at 265 nm |
|  | Concentration of Std.-----------------------------7 |

## Q-ANALYSIS METHOD EQUATIONS



$\mathrm{Q}^{0}=$
Absorbance of mixture at 284 nm
Absorbance of mixture at 265 nm
$A=$ Absorbance of mixture at 265 nm

Now if a mixture of LAM and ABAC were to be analysed a solution of suitable dilution should be prepared in water. The absorbance of the solution at 284.0 nm and 265.0 nm were measured. The values were substituted in above equation (1) and (2) to get concentration of LAM and ABAC.

Twenty tablets of LAM and ABAC in combination were weighed; their average weight was determined and finally crushed to powder
sample. from the triturate, tablet powder equivalent to 300 mg of LAM and 600 mg of ABAC was weighed and transferred to 100 ml volumetric flask and dissolve in 50 ml water and the content was kept in ultrasonicator for 30 min . finally the volume was made up to the mark with water. The solution was filtered through Whatman filter paper No. 41.

This tablet solution was further diluted to obtained $15 \mathrm{mcg} / \mathrm{ml}$ of LAM and $30 \mathrm{mcg} / \mathrm{ml}$ of $A B A C$. The mixed sample solution were analysed to obtained spectra and absorbance value at 284.0 nm and 265.0 nm (Isobastic point) were noted. The concentration of LAM and $A B A C$ were calculated from above equation.

The coefficient correlations were found to be 0.9995 for LAM and 0.9992 for ABAC. The results of tablet analysis and recovery studies obtained by proposed methods were validated by statistical evaluation. The percentage of coefficient of variation for both the drugs was found to be less than $2 \%$. All the developed methods were found to be simple, rapid, precise, economical and accurate for routine simultaneous estimation of ABAC and LAM in tablet dosage form. The recovery was close to $100 \%$ indicating the reproducibility and accuracy of the methods. The Q-Analysis method is rapid and easy because it does not require manual calculations.

## ACKNOWLEDGEMENTS

The authors are thankful to Aurobindo pharmaceuticals Ltd. Hyderabad, for providing gift samples of Lamivudine and Abacavir sulfate

## TABLE 1: RESULTS OFTABLET ANALYSIS

| Method | Tablet <br> sample | Label claim <br> (mg/tab) | Label <br> claim(\%) |  | S.D* |  | \% mean <br> recovery* |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | ABAC | LAM | ABAC | LAM | ABAC | LAM | ABAC | LAM |
| Q <br> method | T1 | 600 | 300 | 100.09 | 100.26 | 0.028 | 0.033 | 99.99 | 100.03 |

$T_{1}$ is the brand of tablet formulation. * denotes $n=6$, average of estimation. ABAC and LAM denotes Abacavir and Lamivudine respectively.

TABLE 2: RECOVERY STUDY DATA FORTABLET FORMULATION

| Meth <br> od | Level of <br> recovery | \% mean <br> recovery | S.D |  | C.V |  | S.E |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | ABAC | LAM | ABAC | LAM | ABAC | LAM | ABAC |
| LAM |  |  |  |  |  |  |  |  |  |
| Q | $80 \%$ | 99.93 | 99.73 | 0.082 | 0.031 | 0.082 | 0.031 | 0.033 | 0.12 |
| Meth | $100 \%$ | 100.0 | 100.1 | 0.097 | 0.049 | 0.0971 | 0.0495 | 0.03 | 0.10 |
| od | $120 \%$ | 4 | 1 | 0.034 | 0.150 | 0.15 | 0.0341 | 0.13 | 0.03 |

* denotes $n=6$, average of six estimation. ABAC and LAM denotes Abacavir and Lamivudine respectively.


Fig 1. Overlain Spectra Of LAM And ABAC Showing Isobastic Point.

## References

1. Indian Pharmacopoeia, govt of India., published by health ministry \& welfare., controller of India, Ghaziabad ,2007,2.
2. S.T., James., Bin, F. and Michael, Bartlett., Wiley interscience , Biomed. Chromatogr. (6/16), 389 .
3. Eunice, Kano., Cristina, d. and Reis, Serra., Internat.J. Pceutics., 2005, 79
4. Cattaneo, Dario., Maggiolo., Chromatogr. Science., 2008, 46489.
5. Lingemann, H., Sevaser, A. and Taroz, A., J. Chromatogr., 2007, 65, 265.
6. Dogan, Topal.,Aozkan, S., Plasma pharmacokinetic, 2005, 297, 73.
7. Joanna, Zheng .,Stevan,T. and Thomas, A., J. Chromatogr., Biomed.Life Science., 1999 ,4,119.
8. Kasture, A.V.Wadodkar, S. G. and Mahadik, K.R.,Pharmaceutical Analysis (Instrumental Methods), 1998,2,3.
9. Swartz, E., krull, S., Analytical chemistry, 1997, 248.
10. Skoog, D. A. Holler, F. J., Fundamentals of analytical chemistry, 1988, 253.
11. Biswas, P.,Tambussi. and Lazzarin A.,Access denied the status of coreceptor inhibition to counter HIV entry, 2007,933.
12. Beckett, A.H., Stenlake, J. B., Practical Pharmaceutical chemistry,. New Delhi, CBS Publisher, 337.
13. Nirogi, R., Bhyrapuneni, G. and kandikere, V., Biomed. Chromatogr. 1999,4,119.
